Exposome Biomonitoring & Environmental Carcinogen Detection Service
Creative Biolabs delivers actionable biological intelligence by addressing the critical gap where traditional, targeted toxicology fails. Recognizing that approximately 90% of chronic disease risk, including cancer, is attributable to the exposome—environmental and lifestyle factors—rather than genetics alone, our service offers a comprehensive solution. We empower clients to accurately assess this crucial cumulative risk using high-resolution analytical techniques. This approach provides a deeper understanding of disease etiology, enabling the development of more effective and safer therapeutic strategies.
Background What We Can Offer Workflow Publication Why Choose Us FAQs Customer Review Related Services Contact Us
Introduction of Exposome Biomonitoring
Exposome biomonitoring represents the cutting edge of preventive medicine, defined as the lifelong, cumulative measurement of environmental exposures and the biological response to them. The field emerged to address the critical fact that environmental and lifestyle factors drive approximately 90% of cancer cases, a major gap that the genome cannot explain. By summarizing all internal and external chemical data using high-resolution mass spectrometry and multi-omics, Creative Biolabs provides a holistic, predictive model of health risk, fundamentally shifting public health and drug safety from reactive compliance to proactive prevention.
Specific Deliverables and Solutions
Quantitative Risk Stratification
Go beyond simple exposure monitoring to identify individuals or cohorts with a critically high internal burden of specific environmental carcinogens (e.g., tobacco metabolites, heavy metals) and their reactive byproducts. This allows for precise population segmentation based on real, measured biological risk.
Novel Biomarker Discovery
Utilize untargeted omics to identify previously uncharacterized xenobiotics or endogenous metabolic shifts that serve as early, predictive indicators of disease initiation (e.g., inflammation, oxidative stress, immune dysregulation).
Intervention Validation and Safety Assessment
Quantitatively measure the biological impact (downstream effect) of public health interventions or pharmaceutical therapies aimed at reducing environmental exposure or mitigating its damage, providing robust data for safety and efficacy reports.
Carcinogenesis Mechanism Mapping
Specialized detection of DNA and protein adducts—the most direct evidence of internal genotoxicity—allows you to map specific exposures to known adverse outcome pathways (AOPs) and elucidate the precise mechanism of action.
Discover How We Can Help - Request a Consultation to discuss your project's specific analytical needs and timeline.
Workflow: Precision, Scale, and Actionable Data Integration
Our workflow is meticulously designed for maximal scientific rigor and data utility, supporting projects from small pilot studies to large-scale, prospective cohort analysis.
Publication
This scoping review underscores the underutilization of exposome research in cancer epidemiology. Analyzing studies, it finds only one employed untargeted method to broadly profile environmental chemicals, with most relying on limited, hypothesis-driven approaches. Key gaps include small sample sizes, a lack of pre-diagnosis longitudinal data, and insufficient integration of social determinants or multi-omics data. The authors advocate for large-scale collaborative efforts, including a global "cancer exposome atlas," to systematically identify novel environmental risk factors and advance primary cancer prevention.
Fig.1 Prospective and multi-omic approaches to decode the exposure-cancer subtype link. 1
Why Choose Us?
Creative Biolabs' leadership in molecular toxicology, coupled with state-of-the-art technological platforms, provides unique advantages for any exposome project, ensuring data quality, scale, and actionable insights.
Our Core Competitive Advantages:
Specialization in Carcinogenesis
Our 20-year foundation in molecular toxicology means we are experts in the detection of carcinogen-specific DNA and protein adducts, offering the most direct and biologically relevant measurement of cancer risk available in the industry.
Unmatched Scale for Cancer Atlas Initiatives
We handle and process large-scale cohort analysis (e.g., 5,000+ samples) and the analysis of prediagnosis biospecimens. This capability is essential to establish critical causality in large epidemiologic studies, directly supporting global "cancer exposome atlas" efforts.
Tiered, Scalable Service Models
We offer three scalable solutions, from targeted toxicant screens for regulatory compliance to full-spectrum, untargeted multi-omics and data integration for novel biomarker discovery, ensuring you only pay for the depth of analysis you require.
Data-Driven Phenotyping
We move beyond raw feature lists by employing proprietary bioinformatic pipelines to provide actionable insights and clear biological interpretations, ensuring your research yields genuine scientific meaning rather than just large datasets.
Experience the Creative Biolabs Advantage - Get a Quote Today to initiate a discussion with our technical team.
FAQs
Why should I choose untargeted exposomics over a standard targeted toxicology panel?
Our untargeted approach provides a comprehensive, agnostic view of your sample's entire chemical space, giving you the best chance to discover novel environmental risk factors.
How does Creative Biolabs handle the huge volume of data generated by untargeted omics?
We specialize in data-driven phenotyping, transforming raw data into interpretable biological insights using proprietary bioinformatics and AOP mapping to identify actionable metabolic shifts and xenobiotics.
Is the service sensitive enough to detect low-level carcinogens or non-persistent chemicals?
Yes. We use triple-quadrupole and mass spectrometry for sub-ppb sensitivity. By measuring DNA/protein adducts, we quantify the cumulative internal damage, providing a more relevant metric of biological effect.
Customer Reviews
-
Precise Adduct Quantitation
The data quality is highly stable, which allows for direct comparison of genotoxic burden across different professional groups, a benefit that previous generic proteomics methods could not provide. - J.***e R
-
Untargeted Discovery Speed
We identified three uncharacterized commercial chemicals that other targeted panels missed, providing the first clear leads for an otherwise vague cohort study. The detailed annotation report greatly reduced our internal bioinformatic processing time. - L.***a C
Related Services
To complement your exposome biomonitoring and environmental carcinogen detection project, Creative Biolabs offers several highly relevant services that can provide additional mechanistic depth:
LC-MS-based Bioanalysis Service
Equipped with advanced LC-MS technologies, Creative Biolabs offers tailored bioanalytical services for small molecules, peptides, and proteins. Our customized solutions support studies from discovery through pre-clinical trials.
Learn More →
Reactive Metabolite Screening Service
Creative Biolabs offers reactive metabolite screening assays (e.g., glutathione, cysteine, cyanide trapping, stable isotope labeling) using liver microsomes/hepatocytes to detect and quantify metabolites, assessing a drug candidate's potential safety risks.
Learn More →
How to Contact Creative Biolabs
Creative Biolabs is your definitive partner for pioneering research in environmental health and disease prevention. Our specialized service combines leading-edge untargeted multi-omics with robust data integration, providing the comprehensive, actionable intelligence needed to solve the complex puzzle of disease etiology.
For detailed scientific information, project quotes, and to learn more about our tiered service models, please reach out to our specialist team. We are ready to help you design a study that maximizes scientific return on investment.
Reference
-
Young, Anna S., et al. "The need for a cancer exposome atlas: a scoping review." JNCI cancer spectrum 9.1 (2025): pkae122. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1093/jncics/pkae122
For Research Use Only | Not For Clinical Use
Download our brochure